



Florentine Hilbers

Kontakt

Florentine Hilbers

Publikationen (4)

Chumsri S, Holmes E, Di Cosimo S, Werner O, Huober J, Dueck A, Sotiriou C, Saura C, Moreno-Aspitia A, Knutson K, Perez E, Van Dooren V, Hilbers F, Carey L, Li Z, Serie D, Norton N, Mashadi-Hosseini A, Tenner K, Brauer H, Warren S, Danahey P, Colon-Otero G, Partridge A, Thompson E. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. *NPJ Breast Cancer* 2022; 8:68.

Chic N, Prat A, Huober J, Saura C, Di Cosimo S, Láng I, de Azambuja E, Wang Y, Hilbers F, Fumagalli D, Salgado R, Nuciforo P, Luen S, Loi S. Tumor Cellularity and Infiltrating Lymphocytes (CeTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. *J Natl Cancer Inst* 2021

Risi E, Di Leo A, Biganzoli L, Sotiriou C, Vitale S, Boccalini G, Romagnoli D, Huober J, Di Cosimo S, Hilbers F, Guarducci C, Bonechi M, McCartney A, Migliaccio I, Benelli M, Biagioni C, Malorni L. An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). *Ther Adv Med Oncol* 2019; 11:1758835919891608.

Di Cosimo S, Verderio P, Apolone G, de Braud F, Piccart M, Baselga J, Huober J, Izquierdo M, de la Pena L, de Azambuja E, Hilbers F, Iorio M, Tiberio P, Pizzamiglio S, Appierto V, Daidone M. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. *Clin Cancer Res* 2019; 25:3887-3895.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch